ACB vs IIPR: How Aurora Cannabis and Innovative Industrial Properties Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACB and IIPR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACB and IIPR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Aurora Cannabis is a Canadian licensed cannabis producer that has spent the past several years reinventing itself. Once one of the most hyped names of the 2018-2019 cannabis boom, it has since exited low-margin Canadian consumer (recreational) cannabis and non-core operations to concentrate on global medical cannabis, which carries higher and more durable margins. In its fiscal 2026 the company reported record medical results: global medical net revenue grew sharply, international medical revenue rose even faster (led by Germany and Poland), and adjusted EBITDA and free cash flow turned meaningfully positive, a real shift from years of cash burn. International medical, its highest-margin segment, now makes up a majority of medical revenue. To feed that demand, Aurora acquired Safari Flower Company, an EU-GMP certified European cultivator, and in February 2026 it completed the divestiture of its controlling stake in Bevo Agtech, its plant-propagation business, further sharpening the focus on medical cannabis.

Full ACB guide

Innovative Industrial Properties, Inc. (NYSE: IIPR) is a real estate investment trust that pioneered the cannabis-focused, sale-leaseback model in the United States. It buys industrial and greenhouse cultivation and processing facilities from state-licensed cannabis operators and leases them back on long-term, triple-net leases, meaning tenants are responsible for property taxes, insurance, and maintenance. Because federally regulated banks have historically been wary of lending to cannabis companies, IIPR stepped in as a specialized source of real estate capital, and rent from these leases is its primary source of income. As of early 2026 the company owned roughly 110 properties totaling around 8.9 million rentable square feet across about 19 states, leased to a few dozen tenants, and has begun describing itself as a diversified REIT with some interest beyond cannabis.

Full IIPR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ACB drivers: International medical cannabis growth; Path to sustained profitability.
• IIPR drivers: High dividend and income appeal; Tenant recovery and re-leasing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. For IIPR, the dominant risk is tenant concentration and credit quality: IIPR leases to a limited number of cannabis operators, and defaults by its largest tenant and others directly threaten rental income and the dividend, which has at times been uncovered by funds from operations.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ACB if you believe its drivers more; IIPR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACB and IIPR guides.

ACB. These points are qualitative and tied to the asOf date; verify live numbers before acting. For a stock like Aurora, headline revenue growth matters less than whether profitability is durable and whether the company can fund itself without issuing more shares, because dilution has repeatedly overwhelmed operating progress in the past. Be cautious with per-share comparisons across time given the reverse-split history, and always check the current share count, cash position, and latest guidance directly in the filings.

IIPR. Figures are approximate, tied to the asOf date, and should be verified against the latest filings before acting. For a REIT, the metrics that matter most are funds from operations (FFO) and adjusted FFO relative to the dividend, plus occupancy and rent collection, rather than a standard P/E ratio. A very high dividend yield reflects elevated perceived risk, not just generosity: the market is pricing in the chance of a cut, so treat the headline yield with caution and check the latest FFO and payout figures.

Headline figures (approximate, Jul 2026): ACB shows business model Canadian cannabis producer pivoting to higher-margin global medical cannabis, with EU-GMP supply into Germany, Poland, and other international markets, revenue trend Medical (especially international) growing fast, but total revenue expected to ease toward earlier levels as low-margin Canadian consumer and non-core units are exited; verify latest figures, profitability Record fiscal 2026 medical results; adjusted EBITDA and free cash flow turned positive, a shift from years of losses, though management guides fiscal 2027 EBITDA lower, share count Around 59 million common shares as of early 2026, reflecting a heavy cumulative reverse-split history (roughly 1-for-120 over time); IIPR shows portfolio ~110 properties, ~8.9 million rentable square feet, across ~19 states (early 2026), tenants A few dozen tenants (around 36); top tenant and several others have defaulted, pressuring rent, quarterly dividend $1.90 per share declared mid-2026 (held steady), implying a double-digit forward yield, dividend coverage At times not fully covered by funds from operations; coverage hinges on resolving defaults and re-leasing.

ACB and IIPR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACB and IIPR exposure against your real portfolio. It is not an investment adviser.